



ImmunOs Therapeutics AG Presents Data from their iosH2 Program at the Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting

Schlieren (Zurich Area), Switzerland. – November 13, 2020

ImmunOs Therapeutics AG (“ImmunOs”), presented preclinical data evaluating iosH2, a novel molecule with high affinity for Leukocyte Immunoglobulin-Like Receptors (“LILRB”), to demonstrate its anti-cancer activity in vitro and in vivo for the treatment of solid tumors at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

The human leukocyte immunoglobulin-like receptor family B (LILRB) acts as check point blockade of the innate immune system by inhibiting leukocyte activation through SHP phosphatase recruitment. Some of the physiological ligands include classical HLA class I molecules, including beta-2-microglobulin (β 2M) free open conformers (OC). Natural HLA open conformers (HLA-OC) expression is known from autoimmune disease leading to pleiotropic immune activation effects through the interaction to LILRB and KIR receptor family members, reducing Treg and MDSC numbers and increased effector T-cell and NK-cell activation is observed, respectively. We have generated an IgG4-HLA-57 open conformer (OC) molecule (iosH2) with high affinity for LILRB molecules and demonstrate its anti-cancer activity in vitro and in vivo.

Conclusion: iosH2 binds to LILRB2 with high affinity, restores immune cell function in vitro and demonstrates anti-tumor activity in different in vivo mouse models. In addition, it acts synergistically in vivo with PD1. iosH2 is a first-in-class OC therapeutic with robust anti-tumor activity modulating key components of immune system. Clinical development is under way and phase I trial is in preparation.

“The mechanism of action of iosH2 and preclinical validation supports further development of iosH2 in clinic as a monotherapy agent and to address PD1 inhibitor resistant tumors.” said Dr. Osiris Marroquin Belaunzaran CSO of ImmunOs Therapeutics AG

“ImmunOs has developed a new class of biologics for the treatment of cancer with focus on the Leukocyte Immunoglobulin-Like Receptor Family B (LILRB). Our differentiated pipeline of candidates activates anti-tumor responses by blocking several specific immune checkpoints with a single agent. We are excited to continue our on-going clinic plans to evaluate iosH2’s safety and efficacy in patients with solid tumors,” said Sean R. Smith CEO of ImmunOs Therapeutics AG.

About ImmunOs Therapeutics AG:

www.immunotherapeutics.com

ImmunOs Therapeutics AG is a spin-off biotechnology company of the Universities of Zurich and Basel. ImmunOs discovers novel human proteins modulating the innate immune system to improve the lives of patients with serious diseases. The lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses. ImmunOs novel platform allows development of multiple multi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune diseases (For more information, please visit www.immunotherapeutics.com)

Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area), Switzerland

info@immunotherapeutics.com